David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.
In a brief SEC filing, the biotech said he had “delivered his resignation […] effective December 28, 2017.”
The brief update said he was leaving to “pursue another professional opportunity,” though that was all she wrote on details. A retained search for a new CMO has begun, with help from Russell Reynolds Associates.
This comes three months after Janssen, the biotech unit of Johnson & Johnson, said it was ditching work with Achillion on a cocktail hep C program, citing a crowded market of innovative meds in this area, namely those from Gilead.
Achillion, with a market cap of around $400 million, was hit hard by the decision as the biotech was working with Janssen on its NS5A inhibitor, odalasvir, for this program in a potential $1 billion biobucks deal before the plug was pulled.
Some had seen Gilead or J&J as potential buyers of the company, but this has not come to fruition, and its shares have taken a hit since J&J’s decision to terminate its hep C deal.
Achillion is also now working on a midstage med, ACH-4471, in patients with untreated paroxysmal nocturnal hemoglobinuria (PNH).
By Ben Adams
Source: Fierce Biotech
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.